4906.5000 65.50 (1.35%)
NSE Jun 27, 2025 15:31 PM
Volume: 113.9K
 

4906.50
1.35%
Motilal Oswal
With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.
Number of FII/FPI investors increased from 524 to 535 in Mar 2025 qtr.
More from Alkem Laboratories Ltd.
Recommended